Family Planning Centers (U.S.) — NAICS 62141

A rollup industry primer for public-market and private investors.

---

1. Overview

NAICS 62141 is the five-digit industry level for Family Planning Centers within the North American Industry Classification System (NAICS), the federal statistical coding scheme for U.S. business. It covers outpatient clinics whose main business is reproductive and sexual health care delivered outside a hospital or a general doctor's office: contraception (birth control), sexually transmitted infection (STI) testing and treatment, cancer and wellness screenings, pregnancy counseling, voluntary sterilization, fertility services, and — where legal — abortion.[4]

The single most important fact for an investor is that this is not a normal for-profit, shareholder-owned industry. The contraception-and-abortion core is dominated by nonprofits (above all Planned Parenthood) and government health departments; money flows in through Medicaid reimbursement, federal Title X grants, private insurance, sliding-scale patient fees, and philanthropy — not equity markets. There is no pure-play, publicly traded family-planning-center company. The one clearly for-profit, consolidating corner is fertility/in-vitro fertilization (IVF), which runs on cash-pay patients and employer benefits. Full detail on all of this — ownership, economics, tickers, and the how-to-invest logic — lives in the child leaf primer for NAICS 621410, which this page rolls up.

---

2. What's inside — and why this level equals its one child

NAICS is hierarchical: sector (2-digit) → subsector (3) → industry group (4) → industry (5) → national industry (6). NAICS 62141 sits inside industry group 6214 (Outpatient Care Centers), in sector 62 (Health Care and Social Assistance).[4]

The five-digit industry 62141 contains exactly one six-digit national industry:

Because there is only one child, NAICS 62141 is identical to NAICS 621410 — same establishments, same employment, same revenue, same definition. The extra digit exists only to complete the NAICS hierarchy; the United States did not subdivide family planning centers into narrower national industries. Everything true of 621410 is true of 62141. For the full treatment — structure, investable universe, economics, demand drivers, regulation, consolidation, and risks — read the 621410 primer. This page gives only the rollup figures and the map.

---

3. Size (this level's federal figures)

These are our ground-truth federal statistics for NAICS 62141. They match the 621410 figures exactly, as they must for a single-child level.

Concentration is near-atomistic: the four largest firms account for just 11.9% of revenue (CR4), the top 8 for 21.4%, the top 20 for 36.1%, and the top 50 for 55.4%; the Herfindahl-Hirschman Index (HHI, a standard 0–10,000 market-concentration measure) is only 90.7.[2] As the child primer explains, that low number reflects statistical structure — Planned Parenthood is legally split into roughly four dozen independently incorporated affiliates, each counted as its own firm — not genuine fragmentation of the brand.

Undercount caveat (important). These figures understate the true reproductive-care footprint. County Business Patterns (CBP) covers only businesses with paid employees and excludes government establishments, so the large network of health-department clinics is out of scope; most physician-run IVF practices are coded to offices of physicians (NAICS 621111) rather than here; and the same services delivered inside federally qualified health centers (FQHCs), hospitals, and doctors' offices count under other NAICS codes. Only about 6% of publicly supported family-planning clinics are Planned Parenthood sites; the majority are FQHCs and health departments not captured in the $4.62 billion.[9] Our federal file contains no industry-wide figure for patient visits, payer mix, or operating margin — where a metric is absent, we say so rather than estimate it.

---

4. Investable universe (where value concentrates)

With only one child industry, value concentrates exactly where the 621410 primer describes it — and not in the safety-net clinics themselves, which are nonprofits and government agencies that cannot be bought. Investors reach the theme indirectly:

• Listed suppliers and adjacent channels ("picks and shovels"): contraceptive drug and device makers — Organon (NYSE: OGN), Bayer (OTC: BAYRY), CooperCompanies (Nasdaq: COO), Perrigo (NYSE: PRGO); direct-to-consumer (DTC) telehealth — Hims & Hers (NYSE: HIMS); fertility benefits, labs, and diversified systems — Progyny (Nasdaq: PGNY), Labcorp (NYSE: LH), HCA Healthcare (NYSE: HCA). In every case family planning is only a slice of the business.[15][16][18][19][20][21][22]
• Private, investor-backed operators — the real equity frontier: fertility and women's-health management-services organizations (MSOs) such as U.S. Fertility, Inception Fertility, and Unified Women's Healthcare, plus venture-backed reproductive-health telehealth and femtech.[23][24][25]

See the 621410 primer for the full table, exposure caveats, and the nonprofit/safety-net operators that sit outside the equity universe.

---

5. How the money works

Unchanged from the child, because the level is the child. The right lens is payer mix and reimbursement, not same-store sales or margins. Four revenue streams dominate: (1) insurance and government reimbursement led by Medicaid, which lists family-planning services as a mandatory benefit;[28] (2) Title X federal family-planning grants (roughly $286.5 million a year nationally, frozen since 2014) and other public funding;[6][7] (3) patient self-pay, sliding-scale fees, and cash-pay fertility; and (4) philanthropy, a major line for Planned Parenthood in particular.[11] The margin lever most specific to the safety-net segment is the federal 340B Drug Pricing Program, which lets qualifying clinics buy contraceptives — including long-acting reversible contraceptives (LARCs) like IUDs and implants — at deep discounts and bill payers at higher rates, cross-subsidizing free care. The economics are volume-driven and thin. Full mechanics are in the 621410 primer.

---

6. Demand drivers

Same as the child: a broad, recurring base (54.3% of U.S. females ages 15–49 were using contraception in 2022–2023[17]); insurance coverage and Medicaid eligibility; public funding levels; the post-Dobbs shift of abortion demand across state lines and increasingly into telehealth (roughly one-quarter of U.S. abortions by 2025[10]); STI/HIV (human immunodeficiency virus) testing volume; employer fertility coverage; and the channel shift toward over-the-counter (OTC) and pharmacy contraception (Opill). Demand is economically resilient but not recession- or policy-proof. See 621410 for detail.

---

7. Regulation

One of the most heavily and turbulently regulated corners of U.S. health care — the rules are the business. The full treatment is in the 621410 primer; in brief, the governing regimes are Title X grant rules (42 CFR § 59.5, including the shifting abortion-counseling "gag rule");[29] Medicaid provider rules (in 2025 the Supreme Court's Medina decision let states disqualify Planned Parenthood from Medicaid networks);[8] the One Big Beautiful Bill Act (OBBBA) one-year Medicaid defunding of large abortion-providing nonprofits, which expired July 4, 2026;[8][13] Dobbs v. Jackson (2022) and the resulting state patchwork of bans, protections, and cross-state "shield laws";[30] FDA rules on contraceptive and abortion medication (mifepristone's telehealth-enabling Risk Evaluation and Mitigation Strategy, or REMS, remains under litigation);[30][31] and structural health-care law — state corporate-practice-of-medicine rules, the Health Insurance Portability and Accountability Act (HIPAA), and the Clinical Laboratory Improvement Amendments (CLIA).[31]

---

8. Consolidation

Identical to the child. "Competition" here is about network adequacy and geography — whether a clinic exists within reach — more than price. The physical-clinic footprint is consolidating and thinning under funding pressure (independent abortion-clinic closures roughly doubled in 2025 versus 2024; Planned Parenthood warned up to ~200 of its ~600 health centers are at risk[11][13][14]), even as affiliates merge into fewer, larger organizations. Meanwhile the category is fragmenting and growing at the digital/retail and fertility edges, where MSOs and telehealth entrants can share labs, technology, benefit contracts, and back office. See 621410 for the full dynamics.

---

9. Risks

The same risks that define 621410 define this level: funding whiplash (Medicaid exclusion, Title X freezes, and defunding riders are the dominant, near-existential risk);[8][13] legal and political risk (state bans, mifepristone litigation, provider criminalization, clinic-targeted TRAP laws);[30][31] reimbursement pressure on thin volume-driven margins;[28] legal-structure risk for the for-profit MSO segments; substitution by telehealth and OTC channels; donor cyclicality; privacy, cyber, and physical-security risk;[31] and concentration on single grants, payers, employer clients, or states. For the listed adjacents, the direct threats are to telehealth prescribing (HIMS), contraceptive-maker pricing and 340B exposure (OGN, Bayer, COO), and fertility/lab volume cyclicality.[15][16] Full discussion in the 621410 primer.

---

10. How to invest & outlook

Because 62141 equals 621410, the investment logic is one and the same. Public-market routes are all indirect — treat listed names as proxies, not measures of the industry, and check each one's actual segment exposure: contraceptive/device makers (OGN, BAYRY, COO, PRGO), DTC telehealth (HIMS), and fertility benefits/labs/diversified systems (PGNY, LH, HCA). There is no ETF or listed operator giving targeted exposure to family-planning centers themselves. Private-market equity in safety-net contraception/abortion clinics is largely unavailable (nonprofits and government); the genuine venture and growth-equity opportunity sits in fertility and women's-health MSOs, reproductive-health telehealth/femtech, and the pharmacy/manufacturing that supplies both clinics and DTC platforms.

Outlook. Demand for contraception and reproductive care is stable-to-growing; the open questions are where it is delivered and who pays. The brick-and-mortar safety net is likely to keep consolidating and thinning under funding pressure even after Planned Parenthood's federal Medicaid eligibility was restored in July 2026, while capital, growth, and margin migrate to the digital/retail edge and the cash-pay fertility segment — which is also where the only real equity opportunities sit. Federal receipts and payroll are useful scale indicators; they should not be used to infer national utilization or earnings. For the complete analysis, see the NAICS 621410 primer, of which this level is a one-to-one rollup.

---

Sources

1. U.S. Census Bureau, County Business Patterns (2023), NAICS 621410 — Family Planning Centers. https://www.census.gov/programs-surveys/cbp.html
2. U.S. Census Bureau, 2022 Economic Census, Concentration Statistics (EC2200CONCENTRATION / EC2200SIZECONCEN), NAICS 621410. https://data.census.gov
3. U.S. Census Bureau, 2022 NAICS Definition — 621410 Family Planning Centers. https://www.census.gov/naics/?input=621410&year=2022
4. IBISWorld, Family Planning & Abortion Clinics in the US — Industry Market Size (2025/2026). https://www.ibisworld.com/industry-statistics/market-size/family-planning-abortion-clinics-united-states/
5. HHS Office of Population Affairs, 2023 Title X Family Planning Annual Report. https://opa.hhs.gov/research-evaluation/title-x-services-research/family-planning-annual-report
6. Congressional Research Service, Title X Family Planning Program (IF10051), 2025. https://www.congress.gov/crs-product/IF10051
7. KFF, An Update on Medicaid, Title X and Planned Parenthood (2025). https://www.kff.org/womens-health-policy/an-update-on-medicaid-title-x-and-planned-parenthood/
8. Guttmacher Institute, Publicly Supported Family Planning Services in the United States; FQHCs and the Family Planning Safety Net. https://www.guttmacher.org/fact-sheet/publicly-supported-FP-services-US
9. Guttmacher Institute, Full-Year 2025 Estimates: Abortion Incidence, Travel, and Telehealth Provision. https://www.guttmacher.org/report/full-year-estimates-show-overall-stability-abortion-incidence-decreased-travel-increased-telehealth-provision
10. Planned Parenthood Federation of America, Annual Report 2024–2025 ("Care continues"). https://www.plannedparenthood.org/
11. The Hill, Planned Parenthood set to regain federal funding as GOP ban expires (2026). https://thehill.com/policy/healthcare/5952223-planned-parenthood-regains-funding/
12. Healthcare Brew, Independent abortion clinic closures double in 2025 (2025). https://www.healthcare-brew.com/stories/2025/12/09/independent-abortion-clinic-closures-double
13. Hims & Hers Health, Inc., Fourth Quarter and Full Year 2025 Financial Results (2026). https://investors.hims.com/
14. Organon & Co., Form 10-K, Fiscal Year 2024. https://www.sec.gov/Archives/edgar/data/1821825/000182182525000006/ogn-20241231.htm
15. Centers for Disease Control and Prevention, Current Contraceptive Status Among Females Ages 15–49: United States, 2022–2023 (NCHS Data Brief 539, 2025). https://www.cdc.gov/nchs/products/databriefs/db539.htm
16. Bayer, Annual Report 2025 — Pharmaceuticals. https://www.bayer.com/en/investors/annual-reports
17. CooperSurgical (CooperCompanies), Paragard Intrauterine Copper Contraceptive. https://www.coopersurgical.com/
18. Progyny, Inc., Investor Relations. https://investors.progyny.com/
19. HCA Healthcare, Specialties / Women's Care. https://www.hcahealthcare.com/patients/specialties
20. Labcorp, Women's Health and Genetic Testing. https://womenshealth.labcorp.com/
21. U.S. Fertility, About US Fertility. https://www.usfertility.com/about/
22. Inception Fertility, About Us (Prelude, CCRM). https://www.inceptionfertility.com/about-us
23. Unified Women's Healthcare / Altas Partners, Investment Announcement. https://www.altas.com/news/unified-womens-healthcare-announces-new-investment-from-altas-partners
24. Medicaid.gov, Mandatory & Optional Medicaid Benefits (family planning). https://www.medicaid.gov/medicaid/benefits/mandatory-optional-medicaid-benefits
25. Electronic Code of Federal Regulations, 42 CFR § 59.5 — Requirements for a Family Planning Project. https://www.law.cornell.edu/cfr/text/42/59.5
26. U.S. Food and Drug Administration, Birth Control; Opill (OTC) Approval. https://www.fda.gov/consumers/womens-health-topics/birth-control
27. U.S. Department of Health and Human Services, HIPAA — Covered Entities and Business Associates. https://www.hhs.gov/hipaa/for-professionals/covered-entities/index.html
28. Centers for Disease Control and Prevention, Clinical Laboratory Improvement Amendments (CLIA). https://www.cdc.gov/clia/
29. American Medical Association, AMA Strengthens Opposition to Corporate Practice of Medicine (2026). https://www.ama-assn.org/press-center/ama-press-releases/ama-strengthens-opposition-corporate-practice-medicine
30. Supreme Court of the United States, Dobbs v. Jackson Women's Health Organization (2022). https://www.supremecourt.gov/opinions/21pdf/19-1392_6j37.pdf
31. KFF, The Intersection of State and Federal Policies on Access to Medication Abortion via Telehealth after Dobbs (2025). https://www.kff.org/womens-health-policy/the-intersection-of-state-and-federal-policies-on-access-to-medication-abortion-via-telehealth-after-dobbs/

Note: this is a rollup page. Citation numbers above map to the fuller Sources list in the NAICS 621410 leaf primer; see that page for the complete set of references, including the additional Planned Parenthood, carafem, Whole Woman's Health, and shield-law sources cited there.